Roundtable Discussion: Is Actinium-225 Ready for Mainstream Clinical Adoption? Balancing Scientific Promise with Development Reality
11:45 am - Wednesday 2nd December 2026
- Evaluating where Actinium-225 offers meaningful clinical advantages over established beta-emitting radionuclides to maximise patient benefit
- Overcoming isotope supply, manufacturing and infrastructure constraints to enable sustainable clinical development and future commercialisation
- Optimising target selection, dosimetry and therapeutic index to improve efficacy while minimising off-target toxicity